A Recurrent Keratin 14 Mutation in Dowling-Meara Epidermolysis Bullosa Simplex in A Chinese Family

J. W. Wu,S. X. Xiao

DOI: https://doi.org/10.1111/j.1468-3083.2008.02930.x

2009-01-01

Journal of the European Academy of Dermatology and Venereology

Abstract:© 2008 The Authors JEADV 2009, 23, 441–496 Journal compilation © 2008 European Academy of Dermatology and Venereology was increased to 80 mg/day, and he was started on mycophenolate mofetil, up to 3 g/day, but did not clear on this regimen after 3 months. He then developed fatigue, insomnia, weakness and weight gain, so prednisone was lowered to 60 mg/day, and mycophenolate mofetil was replaced with oral cyclophosphamide, 100 mg/day. On this regimen, all lesions gradually healed, and prednisone was slowly tapered off. He remained clear on 100 mg/day of cyclophosphamide, which was tapered off after 8 months with no recurrence. His psoriasis returned after prednisone was tapered off and was treated with weekly methotrexate after cyclophosphamide was discontinued. He has done well at 5-month follow-up on 15 mg of methotrexate per week with no recurrence of PV. This patient is of interest because of the development of PV while taking etanercept, a TNF inhibitor that has been proposed as a treatment for PV.5 Although PV may have occurred spontaneously, the development of PV for the first time in this patient while on etanercept and the exacerbation after re-initiating this drug suggests a relationship between PV and etanercept. Etanercept is being studied as a therapy for PV, since the keratinocyte-derived pro-inflammatory cytokine TNF-α has been implicated in the acantholysis characteristically seen in PV.2 Etanercept and other TNF inhibitors represent an important breakthrough in the treatment of skin diseases, however, because these drugs are relatively new, long-term follow-up and reporting of potential side-effects is important in order to better understand the overall safety and efficacy of this class of drugs.